SCHEMBL2894545

SCHEMBL2894545

CCOC(=O)c1cnn(C)c(=O)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
CA12 O43570 3/20 0.46
CA1 P00915 3/20 0.46
CA2 P00918 3/20 0.46
CA7 P43166 3/20 0.46
CA9 Q16790 3/20 0.46
CA14 Q9ULX7 3/20 0.46
ALDH1A1 P00352 4/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
TSHR P16473 1/20 0.45
KDM4E B2RXH2 2/20 0.43
HSD17B10 Q99714 1/20 0.43
BAZ2B Q9UIF8 1/20 0.43
BAZ2A Q9UIF9 1/20 0.43
ESR1 P03372 1/20 0.42
ESR2 Q92731 1/20 0.42
HTT P42858 3/20 0.42
HPGD P15428 2/20 0.42
HSP90AA1 P07900 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17582616 0.83 PDE1B (0.38) CYP2C9CYP2C19ALDH1A1SMN1; SMN2TSHR
SCHEMBL4078995 0.81 ATM (0.47) CA12CA1CA2CA7CA9
SCHEMBL17582560 0.77 PTGS1 (0.46) SMN1; SMN2MAPTMEN1KMT2ACYP1A2
SCHEMBL186256 0.75 PTGS1 (0.49) CYP2C9CYP2C19ALDH1A1KDM4EHPGD
SCHEMBL17582602 0.75 SMN1; SMN2 (0.56) ALDH1A1SMN1; SMN2TSHRTDP1LMNA
SCHEMBL24702015 0.75 PTGS1 (0.42) MEN1KMT2A
SCHEMBL358469 0.75 CYP2C9 (0.47) CYP2C9CYP2C19CA12CA1CA2
SCHEMBL2521960 0.75 KMT2A (0.48) CYP2C9CYP2C19CA12CA1CA2
SCHEMBL763629 0.74 CA12 (0.50) CA12CA1CA2CA7CA9
SCHEMBL25017777 0.74 CYP2C9 (0.42) CYP2C9CYP2C19CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070259862-A1 MGluR5 modulators I ASTRAZENECA AB (SE) 2007-11-08 US claimed
US-7678796-B2 MGluR5 modulators I ASTRAZENECA AB (SE) 2010-03-16 US disclosed
US-7678796-B2 MGluR5 modulators I ASTRAZENECA AB (SE) 2010-03-16 US disclosed
US-7678796-B2 MGluR5 modulators I ASTRAZENECA AB (SE) 2010-03-16 US disclosed
US-20070259862-A1 MGluR5 modulators I ASTRAZENECA AB (SE) 2007-11-08 US disclosed
US-20070259862-A1 MGluR5 modulators I ASTRAZENECA AB (SE) 2007-11-08 US disclosed
US-20070259862-A1 MGluR5 modulators I ASTRAZENECA AB (SE) 2007-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259862-A1 MGluR5 modulators I GRM5, GRM1, GRIK5 CYP2C9 4101/4885CYP2C19 3912/4885CA12 4619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.